Comparison between Saroja Pharma IPO and Unihealth Consultancy IPO.
Saroja Pharma IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Unihealth Consultancy IPO is a SME Bookbuilding proposed to list at NSE SME.
| Saroja Pharma IPO | Unihealth Consultancy IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Fixed Price | Bookbuilding |
| Listing At | NSE SME | NSE SME |
| Lead Managers | Swastika Investmart Ltd. | Unistone Capital Pvt.Ltd. |
| Registrar | Kfin Technologies Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Swastika Investmart Ltd. | Rikhav Securities Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Saroja Pharma IPO is up to ₹8.66 Cr whereas the issue size of the Unihealth Consultancy IPO is up to ₹53.70 Cr. The final issue price of Saroja Pharma IPO is ₹84.00 per share and of Unihealth Consultancy IPO is ₹132.00 per share.
| Saroja Pharma IPO | Unihealth Consultancy IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹126.00 per share | |
| Issue Price (Upper) | ₹132.00 per share | |
| Issue Price (Final) | ₹84.00 per share | ₹132.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 1600 shares | 1000 shares |
| Fresh Issue Size | 10,30,400 shares | 40,68,000 shares |
| Fresh Issue Size (Amount) | up to ₹8.66 Cr | up to ₹53.70 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 10,30,400 shares | 40,68,000 shares |
| Issue Size Total (Amount) | up to ₹8.66 Cr | up to ₹53.70 Cr |
Saroja Pharma IPO opens on Aug 31, 2023, while Unihealth Consultancy IPO opens on Sep 08, 2023. The closing date of Saroja Pharma IPO and Unihealth Consultancy IPO is Sep 05, 2023, and Sep 12, 2023, respectively.
| Saroja Pharma IPO | Unihealth Consultancy IPO | |
|---|---|---|
| Anchor Bid Date | Sep 07, 2023 | |
| Issue Open | Aug 31, 2023 | Sep 08, 2023 |
| Issue Close | Sep 05, 2023 | Sep 12, 2023 |
| Basis Of Allotment (Tentative) | Sep 08, 2023 | Sep 15, 2023 |
| Initiation of Refunds (Tentative) | Sep 11, 2023 | Sep 18, 2023 |
| Credit of Share (Tentative) | Sep 12, 2023 | Sep 20, 2023 |
| Listing date (Tentative) | Sep 13, 2023 | Sep 21, 2023 |
| Anchor Lockin End date 1 | Oct 15, 2023 | |
| Anchor Lockin End date 2 | Dec 14, 2023 |
Saroja Pharma IPO P/E ratio is 23.25, as compared to Unihealth Consultancy IPO P/E ratio of 19.02.
| Saroja Pharma IPO | Unihealth Consultancy IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Standalone)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100.00 | 95.32 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 73.02 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 23.25 | 19.02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹33.77 Cr. | ₹203.28 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 15 | 36.19% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 25 | 20.99% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 2.00 | 1.43 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹3.61 | ₹6.94 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 20.85 | 27.91% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Saroja Pharma IPO Retail Individual Investors (RII) are offered 5,15,200 shares while in Unihealth Consultancy IPO retail investors are offered 5,15,200 shares. Qualified Institutional Buyers (QIB) are offered in Saroja Pharma IPO and 8,15,000 shares in Unihealth Consultancy IPO.
| Saroja Pharma IPO | Unihealth Consultancy IPO | |
|---|---|---|
| Anchor Investor Reservation | 12,18,000 shares | |
| Market Maker Reservation | 54,400 shares | 2,16,000 shares |
| QIB | 8,15,000 shares | |
| NII | 5,15,200 shares | 6,11,000 shares |
| RII | 5,15,200 shares | 14,24,000 shares |
| Employee | ||
| Others | ||
| Total | 10,30,400 shares | 40,68,000 shares |
Saroja Pharma IPO subscribed 8.88x in total, whereas Unihealth Consultancy IPO subscribed 18.22x.
| Saroja Pharma IPO | Unihealth Consultancy IPO | |
|---|---|---|
| QIB (times) | 5.97x | |
| NII (times) | 2.90x | 37.65x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 14.83x | 24.61x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 8.88x | 18.22x |
